RAF1 and cancer: Although there are currently no FDA-approved inhibitors targeting ERK, the recognition that ERK reactivation arises in resistant cancers following prolonged treatment with RAF and MEK inhibitors has generated renewed interest in targeting ERK (see Section 2.7).